Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation
Why the study?
Does cilostazol reduce late lumen loss compared to aspirin in patients treated with Palmaz-Schatz stent implantation?
Population
36 patients treated with Palmaz-Schatz stent implantation
Comparison
Cilostazol for 6 months vs Aspirin for 6 months
Design
RCT, randomly given
Follow-up
6 months
Authors
Discussion
Loading...
Member takes
Implication
Supports cilostazol over aspirin to limit restenosis after stenting; confirms angiographic benefit in this RCT.
Structured PICO
Does cilostazol reduce late lumen loss compared to aspirin in patients treated with Palmaz-Schatz stent implantation?
P
Population
36 patients treated with Palmaz-Schatz stent implantation
I
Intervention
Cilostazol for 6 months
C
Comparator
Aspirin for 6 months
O
Outcome
Late lumen loss at follow-upsurrogate
Cilostazol significantly reduces angiographic late lumen loss compared to aspirin after Palmaz-Schatz stent implantation, suggesting a potential reduction in restenosis.
Cite This Study
Yamasaki et al. (1998) studied this question.